Skip to main content

Cardio/Pulmonary

Dr. John Cush
@RheumNow
Cardiovascular Risk in Axial Spondyloarthritis When a patient with axial spondyloarthritis patient sits in your clinic, their joint inflammation is only half the story. To truly achieve disease control, one should ask: “Am I consistently and aggressively screening them all for https://t.co/t0hLcKIowz
Dr. John Cush
@RheumNow
Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA Which of our RA patients will develop RA-ILD, and how can we better identify these patients? In abstract #2884 at #ACR26 , Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study https://t.co/P96KAcPmWt
Dr. John Cush
@RheumNow
Cardiovascular Risk in Rheumatoid Arthritis What is the link between cardiovascular risk and dementia? In abstract 1454, Michelle Allen and colleagues at Mayo Clinic studied 2,483 adults with incident RA diagnosed between 1980 and 2019. Patients were followed for Alzheimer’s https://t.co/JaITrlZXIt

Cardiovascular Risk in Axial Spondyloarthritis

Sheila Reyes, MD

When a patient with axial spondyloarthritis patient sits in your clinic, their joint inflammation is only half the story. To truly achieve disease control, one should ask: “Am I consistently and aggressively screening them all for cardiovascular risk?"

Mrinalini Dey
@DrMiniDey
Among 2157 men with RA, 24% showed mosaic Y-chromosome loss in some blood cells. This was associated with later RA onset, but not significantly with ILD, CV events or death after adjustment for age, smoking and other factors. #2930 #ACR26 @Rheumnow
Jiha Lee
@JihaRheum
A#2930 mLOY is linked to CVD and ILD in the general population. In RA? Among 2,157 VA men, 24.1% had mLOY, more often with late-onsetRA ≥65y (33% vs 16%). Unadjusted links to ILD, CVD, and death not significant after adjusting for age and smoking. @rheumnow #ACR26
Mrinalini Dey
@DrMiniDey
Do we have a marker for RA-ILD severity? Higher MMP7 was assoc with greater CT involvement and lower DLCO; not FVC or respiratory symptom scores. HRCT & DLCO also more sensitive indicators of RAILD progression and severity than FVC and respiratory PROs #2886 @Rheumnow #ACR26
Mrinalini Dey
@DrMiniDey
How much RA-ILD are we missing? HRCT detected previously undiagnosed ILD in 9.1% of 1169 RA patients with >=2 risk factors. FVC was similar with and without ILD; crackles and lower DLCO were more common with ILD. #2884 #ACR26 @Rheumnow
Akhil Sood MD, MS
@AkhilSoodMD
How well does PREVENT predict HF and total CVD in lupus? Abst 2861 found: - Moderate discrimination for both outcomes (C=0.70 each) - Sensitivity of 53% for HF and 67% for total CVD - PREVENT underestimated both risks across deciles #ACR26 @RheumNow
Audrey Gibson
@Gibson_RheumPAC
Weber et al. (TOGETHER PsO&PsA): 30% lower predicted 10-year CVD risk vs pts IXE mono. suggest that targeting both inflammatory and metabolic pathways may improve CV benefit and potentially reduce long-term CV burden in this high-risk population. @rheumnow #ACR2026 Abstract#2299
Daric Mueller, PA-C
@rheumPAC
Myocardial mayhem: IIMs assoc with cardiac involv such as arrhythmia, heart block, peri or myocarditis. Cohort of 110 IIM pts , 14.5% with cardiac features. Myocarditis and arrhythmia most common. Majority @ IIM Dx. Predictors: male and overlap myositis Ab2595 #ACR26 @RheumNow
Audrey Gibson
@Gibson_RheumPAC

Weber et al: Ixekizumab + tirzepatide improved CV risk factors and calculated CV risk beyond ixekizumab alone in psoriatic disease with obesity. Not proven fewer CV events, but a powerful reason to look beyond joints. @rheumnow #ACR2026 #ACRBest Abstract#2299

sheila
@RHEUMarampa
Data from hopkins lupus cohort compared early vs late CV events in SLE Highest rate of CVEs within 2 yrs of dx; 8x higher vs. pre-Dx period RFs for early CVEs - >45yo, obesity, DM, HTN, hyperlipid, LAC RFs for late CVEs similar to early + smoking, low c3 @RheumNow #ACR26 Abs2247 https://t.co/FIyB59930J
Audrey Gibson
@Gibson_RheumPAC
Plot twist in GOUT! Does a gout flare really trigger a cardiovascular event? CARES trial analysis found NO significant association between flares and subsequent CV events. Could flare medications—not inflammation—help explain prior findings?Yokose et al. | #1820 @RheumNow #ACR26
×